From understanding diseases to drug design: can artificial intelligence bridge the gap?

被引:9
|
作者
Pushkaran, Anju Choorakottayil [1 ]
Arabi, Alya A. [1 ]
机构
[1] United Arab Emirates Univ, Coll Med & Hlth Sci, Dept Biochem & Mol Biol, POB 15551, Al Ain, U Arab Emirates
关键词
Artificial intelligence; Machine learning; Disease identification; Drug discovery; TARGET IDENTIFICATION; DIABETIC-RETINOPATHY; NEURAL-NETWORKS; DEEP; CLASSIFICATION; VALIDATION; PREDICTION; ALGORITHM; DISCOVERY; CANCER;
D O I
10.1007/s10462-024-10714-5
中图分类号
TP18 [人工智能理论];
学科分类号
081104 ; 0812 ; 0835 ; 1405 ;
摘要
Artificial intelligence (AI) has emerged as a transformative technology with significant potential to revolutionize disease understanding and drug design in healthcare. AI serves as a remarkable accelerating tool that bridges the gap between understanding diseases and discovering drugs. Given its capacity in the analysis and interpretation of massive amounts of data, AI is tremendously boosting the power of predictions with impressive accuracies. This allowed AI to pave the way for advancing all key stages of drug development, with the advantage of expediting the drug discovery process and curbing its costs. This is a comprehensive review of the recent advances in AI and its applications in drug discovery and development, starting with disease identification and spanning through the various stages involved in the drug discovery pipeline, including target identification, screening, lead discovery, and clinical trials. In addition, this review discusses the challenges that arise during the implementation of AI at each stage of the discovery process and provides insights into the future prospects of this field.
引用
收藏
页数:39
相关论文
共 50 条
  • [41] Artificial intelligence approaches for rational drug design and discovery
    Duch, Wlodzislaw
    Swaminathan, Karthikeyan
    Meller, Jaroslaw
    CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (14) : 1497 - 1508
  • [42] Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design
    Vora, Lalitkumar K.
    Gholap, Amol D.
    Jetha, Keshava
    Thakur, Raghu Raj Singh
    Solanki, Hetvi K.
    Chavda, Vivek P.
    PHARMACEUTICS, 2023, 15 (07)
  • [43] unleashing the Power of Artificial Intelligence for Personalised Drug Design
    Zervou, Michaela Areti
    Doutsi, Effrosyni
    Tsakalides, Panagiotis
    ERCIM NEWS, 2023, (134):
  • [44] The significance of artificial intelligence in drug delivery system design
    Hassanzadeh, Parichehr
    Atyabi, Fatemeh
    Dinarvand, Rassoul
    ADVANCED DRUG DELIVERY REVIEWS, 2019, 151 : 169 - 190
  • [45] Application of Computational Biology and Artificial Intelligence in Drug Design
    Zhang, Yue
    Luo, Mengqi
    Wu, Peng
    Wu, Song
    Lee, Tzong-Yi
    Bai, Chen
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (21)
  • [46] Artificial intelligence in multi-objective drug design
    Luukkonen, Sohvi
    van den Maagdenberg, Helle W.
    Emmerich, Michael T. M.
    van Westen, Gerard J. P.
    CURRENT OPINION IN STRUCTURAL BIOLOGY, 2023, 79
  • [47] Enzyme engineering: from artificial design to artificial intelligence
    Wang Y.
    Fu Y.
    Chen J.
    Huang J.
    Liao L.
    Zhang Y.
    Fang B.
    Huagong Xuebao/CIESC Journal, 2021, 72 (07): : 3590 - 3600
  • [48] How Virtual Machinery Can Bridge the "Explanatory Gap", in Natural and Artificial Systems
    Sloman, Aaron
    FROM ANIMALS TO ANIMATS 11, 2010, 6226 : 13 - 24
  • [49] Explainable Domain-Specific Artificial Intelligence for Bridge Engineering and Design
    Kraus, Michael A.
    BETON- UND STAHLBETONBAU, 2022, 117 (10) : 795 - 804